Tu Shen

Tu Shen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Redox Biology
Verified
Journal Article
Open access
QWQiaoling Wu
Qiaoling Wu
DZDongbo Zhang
Dongbo Zhang
SDSiqi Dai
Siqi Dai
FLFeifei Liu
Feifei Liu
WZWei Zhang
Wei Zhang
TSTu Shen
Tu Shen
Renal ischemia-reperfusion (I/R) injury triggers significant oxidative stress and inflammation, leading to tubular epithelial cell (TEC) damage. This study investigates the protective role of Desflurane (DFE) in renal I/R by modulating the ITGB1/CD9 signaling pathway and mitigating oxidative damage. Single-cell RNA sequencing (scRNA-seq) and transcriptome analysis identified ITGB1 as a key regulatory gene in TECs during renal I/R. The effects of DFE on ITGB1/CD9 expression were evaluated through in vitro experiments using RT-qPCR, Western blot, and TUNEL assays. A mouse model of renal I/R was employed to assess renal function and oxidative stress markers under DFE treatment. DFE reduced ITGB1 and CD9 expression, resulting in decreased TEC apoptosis and enhanced proliferation. In vivo, DFE-treated mice exhibited improved renal function, with significantly lower serum creatinine and blood urea nitrogen (BUN) levels. Additionally, DFE reduced oxidative stress, as indicated by decreased malondialdehyde (MDA) and myeloperoxidase (MPO) activity, alongside increased superoxide dismutase (SOD) activity. DFE confers renal protection against I/R by modulating the ITGB1/CD9 axis and reducing oxidative stress, offering a promising therapeutic strategy for mitigating kidney damage.

1 November 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
BDBo-Ran Deng
Bo-Ran Deng
YZYang Zhang
Yang Zhang
ZXZi-Feng Xie
Zi-Feng Xie
DWDing-Ding Wang
Ding-Ding Wang
TZTao Zeng
Tao Zeng
QWQiao-Ling Wu
Qiao-Ling Wu
Purpose: The debate continues over the differential impact of remimazolam vs propofol on hemodynamic stability. This study aims to elucidate the effects of a combination of remimazolam and esketamine vs propofol and esketamine on hemodynamic parameters in elderly patients undergoing painless colonoscopies. Patients and Methods: We conducted a randomized controlled trial involving 754 patients, divided equally between two treatment groups. The remimazolam-esketamine group (RE group) received 0.15 mg/kg of remimazolam and 0.3 mg/kg of esketamine. Conversely, the propofol-esketamine group (PE group) was administered 1.5 mg/kg of propofol with 0.3 mg/kg of esketamine. Primary outcomes focused on the incidence of hypotension. Secondary outcomes assessed were other hemodynamic adverse events, intraoperative blood pressure and heart rate fluctuations, usage of vasoactive agents, sedation efficacy, and additional adverse reactions. Results: Hypotension occurred significantly less frequently in the RE group (9.78%, 95% confidence interval[CI]: 6.67– 12.87%) compared to the PE group (23.57%, 95% CI: 21.22– 30.52%), P< 0.001. The RE group also showed lower incidences of sinus tachycardia, sinus bradycardia, and required less support from vasoactive agents (P< 0.001). Additionally, the RE group experienced smaller fluctuations in blood pressure and heart rate (P< 0.05). Both groups achieved a 100% sedation success rate. Notably, the RE group had a longer induction period but a quicker recovery time (P< 0.001), and lower rates of respiratory depression (P=0.006) and injection pain (P< 0.001). Conclusion: Remimazolam combined with esketamine offers superior hemodynamic stability and significantly reduces adverse event rates compared to propofol plus esketamine in elderly patients undergoing painless colonoscopies, while maintaining effective sedation.

29 February 2024 in The FASEB Journal
Verified
Journal Article
Closed access
KZKun Zhu
Kun Zhu
HZHanyue Zhang
Hanyue Zhang
YLYan Luan
Yan Luan
BHBaoqi Hu
Baoqi Hu
TSTu Shen
Tu Shen
XZXiaoyan Zheng
Xiaoyan Zheng

5 February 2024 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
BDBoran Deng
Boran Deng
DWDingding Wang
Dingding Wang
ZXZifeng Xie
Zifeng Xie
YWYongqin Wang
Yongqin Wang
LHLi Huang
Li Huang
TSTu Shen
Tu Shen
Background: Sufentanil in combination with dezocine or esketamine is often used for postoperative analgesia. However, there is a lack of clinical evidence of efficacy. This study compares the analgesic effects of esketamine and dezocine combined with sufentanil for relieving pain after laparoscopic cholecystectomy(LC). Methods: A total of 58 patients were randomly assigned to the esketamine group (ES group) and dezocine group (DE group). In the ES group, 1.5 mg/kg esketamine was used. In the DE group, 0.3 mg/kg dezocine was used. Primary outcome measures were Visual Analog Scale (VAS) score at 4 h, 8 h, 24 h and 48 h after surgery. The second outcome measures were Interleukin-6 (IL-6) and C-reactive protein (CRP) levels in the serum 10 minutes before anesthesia induction, and at 24 h and 48 h after surgery. Results: The VAS scores at 4 h, 8 h, 24 h and 48 h after the surgery in the ES group vs DE group were 2.70 vs 3.50(P=0.013),2.35 vs 3.15(P=0.004),1.69 vs 2.58(P=0.002), and 1.50 vs 2.26(P=0.002), respectively. The serum IL-6 concentrations 10 minutes before anesthesia induction, and at 24 h and 48 h after surgery in the ES group and DE group were 34.39 and 34.12(P=0.901),112.33 and 129.60(P=0.014), and 89.69 and 108.46(P<0.001), respectively. The CRP levels in serum 10 minutes before anesthesia induction, and at 24 h and 48 h after the surgery in the ES group and DE group were 5.99 and 5.86(P=0.639), 28.80 and 35.37(P<0.001), and 23.17 and 30.11(P<0.001), respectively. Conclusion: For postoperative pain after LC, 1.5mg/kg esketamine provided better analgesia and reduced inflammation levels than 0.3mg/kg dezocine. Trial registration: This trial was registered in the China Clinical Research Information Center in 31/05/2023 : https://www.chictr.org.cn/bin/home (Registration number: ChiCTR2300072011).

12 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
TYTao Yu
Tao Yu
HZHanyue Zhang
Hanyue Zhang
CZChuang Zhang
Chuang Zhang
GMGuorui Ma
Guorui Ma
TSTu Shen
Tu Shen
ZZZhichao Zhang
Zhichao Zhang
Neural stem/progenitor cells (NSPCs) in the subventricular zone (SVZ) of the central nervous system (CNS) are critical for tissue repair following injury or disease. These cells retain the capacity to proliferate, migrate, and differentiate into neurons, astrocytes, and oligodendrocytes, making them a promising therapeutic target for neurodegenerative disorders and traumatic injuries. However, the molecular mechanisms regulating their proliferation remain incompletely understood. This study investigates the role of cAMP responsive element-binding protein 5 (CREB5) in the proliferation of rat SVZ-derived NSPCs and elucidates its regulatory mechanism. Using RNA interference, we demonstrated that CREB5 knockdown significantly reduced cell viability, neurosphere formation capacity, and the number of proliferating cells (BrdU- and Ki-67-positive cells) both in vitro and in vivo. In contrast, CREB5 overexpression played opposing roles in cell proliferation. Additionally, alteration of CREB5 expression did not affect apoptosis, as assessed by TUNEL staining, indicating a specific role in proliferation rather than in cell death. Mechanistically, we identified Nuclear Factor One X (NFIX) as a transcriptional target of CREB5. CREB5 binds to the AP-1 site in the NFIX promoter, enhancing its expression. CREB5 knockdown inhibited NFIX expression, while CREB5 overexpression exerted the opposite function. ChIP and luciferase reporter assays further confirmed that CREB5 directly regulates NFIX promoter activity. More importantly, alteration of NFIX expression could reverse the effect of CREB5 on NSPC proliferation. These findings highlight CREB5 as a key regulator of NSPC proliferation through its interaction with NFIX, providing a potential therapeutic target for stem cell-based treatments of CNS disorders.

11 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FMFan Miao
Fan Miao
HWHuimiao Wang
Huimiao Wang
ZLZhong Liu
Zhong Liu
KWKexin Wang
Kexin Wang
WWWanling Wang
Wanling Wang
TSTu Shen
Tu Shen
To explore the anesthetic efficacy of ropivacaine combined with compound betamethasone in iliac fascial space nerve block analgesia (IFNBA) in patients receiving artificial femoral head replacement (AFHR), and to provide a theoretical basis for the selection of clinical anesthetic drugs. From January 2022 to June 2022, 70 patients requiring IFNBA analgesia undergoing AFHR surgery at our hospital were included in this prospective study. Using Excel randomization, 70 patients were divided into study group (n = 35) and control group (n = 35). The study group received ropivacaine combined with compound betamethasone analgesia regimen, while the control group only received ropivacaine analgesia regimen. In addition to patients’ general baseline clinical characteristics, outcomes indicators included preoperative and postoperative visual analogue scale (VAS) pain scores, preoperative and postoperative Ramsay sedation scores, preoperative and postoperative levels of inflammatory cytokines, duration of analgesia and patient satisfaction in both groups were collected. At 12 h and 24 h after surgery, the static and dynamic VAS pain score of the study group was significantly lower than that of the control group (P < 0.05). At 6 h and 12 h after surgery, the Ramsay sedation score of the study group was significantly higher than that of the control group (P < 0.05). The level of inflammatory cytokines in the study group was significantly lower than that in the control group at the completion of surgery, 24 h and 72 h after surgery (P < 0.05). In addition, the study group had a significantly longer duration of postoperative analgesia and significantly better patient satisfaction (P < 0.05). Especially for patients receiving AFHR, in IFNBA, ropivacaine combined with compound betamethasone has better analgesic effect, higher patient satisfaction, and can effectively reduce the level of inflammatory status, which is worthy of clinical application and promotion.